GlobeNewswire·Nov 10, 2026, 4:03 PM ET

Braveheart Bio Reports Third Quarter 2026 Financial Results and Provides Business Update

Braveheart Bio presented 52-week open-label extension data for BHB-1893 at AHA Scientific Sessions 2026, showing rapid improvements in pVO2 & KCCQ-CSS with 67% of patients achieving LVOT-G below 30 mmHg by Week 1.
The company initiated enrollment in the LIONHEART-HCM Phase 3 trial for obstructive HCM (oHCM) with an interim analysis expected in the second half of 2027.
TRUEHEART-HCM (Phase 2b fixed-dose oHCM) & NOBLEHEART-HCM (Phase 3 non-obstructive HCM) are on track to initiate in the first half of 2027.
Hengrui Pharma completed enrollment in its Phase 3 oHCM trial in China, with topline results expected in the first half of 2027.
Preclinical & clinical data indicate BHB-1893 improves diastolic function while preserving systolic performance, with 52-week nHCM data expected in early 2027.
Financial results for Q3 2026 reported cash, cash equivalents & investments of $503.5 million, providing a runway into 2029.
R&D expenses for the quarter were $17.5 million, driven by clinical trial costs & a $1.0 million milestone payment to Hengrui Pharma.
General & administrative expenses reached $12.6 million, including $7.8 million in non-cash stock-based compensation.
The company reported a net loss of $26.5 million ($0.51 per share) for the three months ended September 30, 2026, compared to $59.1 million in the prior year period.
Braveheart Bio completed an upsized IPO in August 2026, raising approximately $439.9 million in gross proceeds.

Company: Braveheart Bio, Inc.
Keywords: Nasdaq:BRVE, Braveheart Bio, Inc., biotechnology, cardiology, cardiomyopathy, pharmaceuticals